FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, in particular to an isolated antibody or an antigen-binding fragment thereof capable of specifically binding to both fibroblast growth factor receptor 2b (FGFR2b), and FGFR1b, a method for production thereof, as well as a conjugate and a composition containing same. Also disclosed is an isolated polynucleotide encoding said antibody or a fragment thereof, as well as a host cell and a vector containing same. Invention also relates to a method for diagnosing a disease or condition associated with FGFR2b and/or FGFR1b, a method for detecting the presence or amount of FGFR2b and/or FGFR1b in a sample, as well as to a method for the prediction of a disease or condition associated with FGFR2b and/or FGFR1b in a subject, comprising the use of said antibody or fragment thereof.
EFFECT: invention is effective for treating a disease or condition associated with FGFR2b and/or FGFR1b.
41 cl, 12 dwg, 5 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL ANTI-FGFR2B ANTIBODIES | 2020 |
|
RU2841589C1 |
| NOVEL ANTI-FGFR2B ANTIBODIES | 2020 |
|
RU2840536C1 |
| TIGIT ANTIBODIES AND USE THEREOF | 2020 |
|
RU2827445C2 |
| IMMUNOTHERAPY USING ANTIBODIES BINDING PROGRAMMED CELL DEATH PROTEIN LIGAND 1 (PD-L1) | 2017 |
|
RU2766582C2 |
| ANTIBODIES AGAINST PD-L1 AND THEIR OPTIONS | 2017 |
|
RU2770590C2 |
| ANTI-CLAUDIN 18.2 ANTIBODY AND USE THEREOF | 2020 |
|
RU2822550C2 |
| IMMUNOTHERAPY USING ANTIBODIES BINDING PROTEIN 1 OF PROGRAMMED CELL DEATH (PD-1) | 2017 |
|
RU2768404C2 |
| ANTIBODIES SPECIFIC TO MMP9 | 2015 |
|
RU2714043C2 |
| ANTIBODY TO B7-H4, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2792748C2 |
| ANTI-PD-1 ANTIBODIES | 2017 |
|
RU2752832C2 |
